Scientists have a new trick to tackle TDP-43: antibodies delivered via adeno-associated virus. In the September 3 Molecular Therapy, scientists led by Damien Nevoltris at AC Immune, Lausanne, ...
(A) Generation of the novel AAVT42 vector by directed evolution and in vivo screening. The cap genes of AAV1, AAV2, AAV3B, AAV4, and AAV6-9 were mixed, after digestion, denaturation, and reannealing, ...
Age-related macular degeneration (AMD) is the leading cause of blindness among older adults. The exudative or ‘wet’ form of the disease is characterized by the growth of abnormal blood vessels from ...
AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing partner JCR Pharmaceuticals to develop genomic medicines. Under the deal, ...
Osaka, Japan - A research team at The University of Osaka has unveiled the molecular mechanism behind genome ejection from adeno-associated virus (AAV) vectors, a crucial delivery vehicle in gene ...
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) today announced that it has entered into a license agreement with Alexion, AstraZeneca Rare Disease (“Alexion”), for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results